Ying Du Sells 24,543 Shares of Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du sold 24,543 shares of the firm’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $17.46, for a total value of $428,520.78. Following the sale, the chief executive officer directly owned 1,192,840 shares of the company’s stock, valued at $20,826,986.40. This represents a 2.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ying Du also recently made the following trade(s):

• On Thursday, May 14th, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $20.09, for a total transaction of $1,004,500.00.
• On Monday, April 6th, Ying Du sold 2,653 shares of Zai Lab stock. The shares were sold at an average price of $20.45, for a total transaction of $54,253.85.
• On Thursday, April 2nd, Ying Du sold 5,576 shares of Zai Lab stock. The stock was sold at an average price of $20.39, for a total transaction of $113,694.64.

Zai Lab Stock Performance

NASDAQ ZLAB opened at $19.00 on Wednesday. The stock has a market cap of $2.15 billion, a PE ratio of -11.73 and a beta of 0.78. The firm has a 50-day moving average of $19.19 and a 200-day moving average of $18.96. Zai Lab Limited Unsponsored ADR has a 52-week low of $15.96 and a 52-week high of $41.20.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings results on Wednesday, April 1st. The company reported ($0.50) EPS for the quarter. The company had revenue of $99.61 million during the quarter. Zai Lab had a negative net margin of 39.29% and a negative return on equity of 24.32%. As a group, analysts predict that Zai Lab Limited Unsponsored ADR will post -2.23 EPS for the current fiscal year.

Analysts Set New Price Targets

ZLAB has been the topic of several research reports. Wall Street Zen downgraded Zai Lab from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. JPMorgan Chase & Co. dropped their price target on Zai Lab from $39.00 to $32.00 and set an “overweight” rating for the company in a report on Wednesday, March 18th. Weiss Ratings upgraded Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. Finally, Citigroup decreased their price objective on Zai Lab from $47.00 to $44.00 and set a “buy” rating on the stock in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Zai Lab has a consensus rating of “Moderate Buy” and an average price target of $40.00.

Institutional Trading of Zai Lab

A hedge fund recently raised its position in Zai Lab stock. SG Americas Securities LLC boosted its stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,396 shares of the company’s stock after purchasing an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 41.65% of the company’s stock.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.